Dr. Vance M. Wright-Browne, MD

Dr. Wright-Browne practices at Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Osage Beach, Missouri.

Dr. Wright-Browne's NPI, 1528059227, was assigned on November 2, 2005. Dr. Wright-Browne graduated from University of the West Indies Faculty of Medical Sciences in 1987. Dr. Wright-Browne holds Florida license ME70098.

Dr. Wright-Browne's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West, at 54 Hospital Dr, Osage Beach, MO 65065 in Camden County. The practice phone is (239) 541-4633.

Dr. Wright-Browne's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Osage Beach, Missouri. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Wright-Browne to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wright-Browne practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Wright-Browne's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Wright-Browne is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Wright-Browne's licenses on file in 3 states: Florida, Texas and Connecticut.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease and lung cancer among the conditions Dr. Wright-Browne treats.

CMS data shows 168,481 Medicare services from Dr. Wright-Browne across 52 procedure codes in 2024, for 1,334 Medicare patients. Medicare paid $1,366,848 for them. Every service was in an office.

CMS counts 1,334 Medicare patients who saw Dr. Wright-Browne in 2024. The largest group is 75 to 84, with 558 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wright-Browne's median patient age at 71, with 72% women.

In 2024, Dr. Wright-Browne wrote 2,085 Medicare Part D claims for 433 patients. 81% of them were for generic drugs. CMS names the drug for 1,734 of them, across 46 drugs with 11 or more claims each, at $2,969,934 in total drug cost. In 2023, CMS named 2,089 claims across 55 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Wright-Browne for performance year 2024, reported as part of a group.

Dmand AI links 5 papers to Dr. Wright-Browne. Dr. Wright-Browne's most frequent co-authors are Zeev Estrov, MD and Kenneth McClain, MD.

Dmand AI links Dr. Wright-Browne to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Neoplasm Metastasis and Neoplastic Processes. Open Payments lists research payments to Dr. Wright-Browne that name 1 trial.

CMS Open Payments shows 231 general payments to Dr. Wright-Browne from 42 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 96% of the total. Bristol-Myers Squibb Company paid the most, $599. It also lists 2 research payments totaling $5,867 in 2022, naming 1 clinical trial.

Dmand AI lists 2 awards for Dr. Wright-Browne, most recently CMS Stage 1 EHR in 2014.

Dr. Wright-Browne graduated from University of the West Indies Faculty of Medical Sciences in 1987.

Dr. Wright-Browne is in network with 7 carriers, including Cigna, United Healthcare and Elevance. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.